Medical News

RSS

AmerisourceBergen increases quarterly dividend 25% to $0.10 per common share

The Board of Directors of AmerisourceBergen Corporation today increased the Company's quarterly dividend rate 25 percent to $0.10 per common share from $0.08 per common share.

12 Nov 2010

Reata to present bardoxolone methyl Phase 2b clinical trial data for CKD, type 2 diabetes at ASN Conference

Reata Pharmaceuticals today announced that the company will present data on the primary endpoint from a pivotal Phase 2b clinical trial of bardoxolone methyl in patients with chronic kidney disease (CKD) and type 2 diabetes. The data will be presented in a late-breaking oral presentation at the American Society of Nephrology (ASN) Renal Week Conference to be held November 16-21, 2010, in Denver, Colorado.

12 Nov 2010

Veterans and caregivers face ongoing challenges

WebMD: "When veterans with service-related injuries or illness need caregivers, the role typically falls on women, usually spouses or partners," according to a new study by the National Alliance for Caregiving and the United Health Foundation. The study "reports that 96% of veterans' caregivers are women, compared to an overall nationwide finding that 65% of family caregivers are women.

12 Nov 2010

Forest enters commercialization collaboration with Janssen for Bystolic and Savella in Canada

Forest Laboratories, Inc. announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive collaboration and distribution agreement for Bystolic® (nebivolol) and Savella® (milnacipran HCl) in Canada with Janssen Pharmaceutica, NV and Janssen Pharmaceutical respectively, on behalf of Janssen Inc., which will market the products in Canada.

12 Nov 2010

PenCLAHRC provides funding to support C. difficile research

The Peninsula Collaboration for Leadership in Applied Health Research and Care (PenCLAHRC) has provided funding to support joint research between the University of Exeter and the Royal Devon & Exeter NHS Foundation Trust to investigate why some cases of Clostridium difficile infection (CDI) are more difficult to treat than others and also why some cases result in more incidences of relapses.

12 Nov 2010

ESMO-symposium to highlight recent advancement in cancer biology

This ESMO-symposium will allow bed-side oriented oncologists to grasp key and timely-issues related to cancer biology. All presentations will have a clear focus towards potential clinical implications thus helping clinicians fully comprehend the major consequences that new developments in cancer biology may have in daily care.

12 Nov 2010

Diabetic drug may retard growth of fluid-filled cysts in PKD: Research

Researchers report that a drug commonly used to treat diabetes may also retard the growth of fluid-filled cysts of the most common genetic disorder, polycystic kidney disease.

12 Nov 2010

Aeras receives grant to develop new vaccines for TB

The Aeras Global TB Vaccine Foundation is pleased to announce that the Netherlands Ministry of Foreign Affairs has renewed its funding to Aeras with a pledge of an additional 11.7 million over four years (2011-2014) to further its efforts to develop new vaccines to help combat the global epidemic of tuberculosis.

12 Nov 2010

WHO annual global TB report released

The WHO on Thursday released its annual report on global tuberculosis control, which showed that in 2009 there were 9.4 million new tuberculosis cases and 1.7 million people died of the disease, Reuters reports.

12 Nov 2010

New catheter device for abdominal aortic aneurysm

William E. Sorfleet had a life-threatening abdominal aortic aneurysm, but at age 82, he was too old for major invasive surgery to repair the bulging blood vessel. So vascular surgeon Dr. Ross Milner of Loyola University Hospital repaired the aneurysm with a catheter device instead of a scalpel. The catheter, inserted through an artery, deployed a device called a stent graft that repaired the aneurysm.

12 Nov 2010

33rd CTRC-AACR Symposium to feature breast cancer research

The 33rd CTRC-AACR San Antonio Breast Cancer Symposium will feature the latest findings in prevention, epidemiological, laboratory, translational and clinical breast cancer research. This year's symposium will highlight new therapies in the pipeline, new approaches with existing agents and emerging biology that will affect the quest for personalized medicine.

12 Nov 2010

GPI launches new advocacy coalition to advance embryonic stem cell research in U.S.

The Genetics Policy Institute (GPI) today announced the launch of a new advocacy coalition of 30 organizations to foster public awareness and advance the cause of embryonic stem cell research in the United States.

12 Nov 2010

COMP issues positive opinion for Celsion's ThermoDox Orphan Drug Designation

Celsion Corporation, a leading oncology drug development company, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the application for Orphan Drug Designation for ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer.

12 Nov 2010

Insurance commissioners: Miss. Head calls changes 'mind boggling' and partly 'socialist'; anthem challenges Maine superintendent's no-profit ruling for individual plans

Mississippi state Insurance Commissioner Mike Chaney said Wednesday that the volume of changes under the federally mandated health care reform are 'mind boggling' and partly come from 'pure socialist communist ideas.

12 Nov 2010

NaturalNano's HNT can improve separation of CTCs from blood

NaturalNano, Inc. announced that Andrew Hughes is presenting today research from Cornell University's Department of Biomedical Engineering that reports significant improvement in the ability of medical devices in development to target the separation of circulating tumor cells (CTCs) from blood are significantly improved by the use of NaturalNano's Halloysite Nanotubes (HNT) as part of the surface. The devices are designed to remove CTCs from the blood of cancer patients as part of a more personalized approach to cancer treatment.

12 Nov 2010

Acetylon receives two grants under QTDP program to advance HDAC6 inhibitor drug candidate

Acetylon Pharmaceuticals, Inc. today announced that it has been awarded two grants totaling $488,000 under the Qualifying Therapeutic Discovery Project (QTDP) program.

12 Nov 2010

Bristol-Myers Squibb announces first large-scale diabetes initiative to develop self-management program

The Bristol-Myers Squibb Foundation today announced Together on Diabetes: Communities Uniting to Meet America's Diabetes Challenge, a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office in their homes and communities and for the course of their disease.

12 Nov 2010